SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy

Mario Tumbarello, Livio Pagano, Gaspare Guglielmi, Giordana Martino, Alessandro Busca, Federica Lessi, Luisa Verga, Anna Candoni, Chiara Cattaneo, Simone Cesaro, Mario Delia, Gianpaolo Nadali, Rosa Fanci, Marco Picardi, Leonardo Potenza, Annamaria Nosari, Franco Aversa

Risultato della ricerca: Contributo in rivistaArticolo in rivista

1 Citazioni (Scopus)

Abstract

Posaconazole demonstrated clinical superiority over fluconazole and itraconazole for prophylaxis of mold infections, although concerns exist regarding the high acquisition cost for posaconazole. In this respect, we sought to analyze the costs of antifungal prophylaxis in patients with acute myeloid leukemia (AML) who received prophylactic posaconazole (n = 510, 58%), itraconazole (n = 120, 14%) or fluconazole (n = 175, 20%) during induction chemotherapy. The estimated cost of antifungal prophylaxis as well as the costs of subsequent systemic antifungal therapy for treatening an invasive fungal infections (IFI) was higher in the posaconazole group compared to itraconazole and fluconazole groups. Based on the Monte Carlo simulations, the itraconazole group had the highest cost, followed by the posaconazole and fluconazole group, although the overall survival was higher in the posaconazole group as compared to the other groups. In conclusion, the cost of prophylaxis with posaconazole in AML patients compares favorably with conventional antifungal agents.
Lingua originaleEnglish
pagine (da-a)2859-2864
Numero di pagine6
RivistaLEUKEMIA & LYMPHOMA
Volume58
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Antifungal prophylaxis
  • Cancer Research
  • Hematology
  • Oncology
  • acute myeloid leukemia
  • antifungal treatment
  • cost

Fingerprint Entra nei temi di ricerca di 'SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy'. Insieme formano una fingerprint unica.

Cita questo